Summary & Overview
HCPCS Q5138: IV ustekinumab-auub (Wezlana) biosimilar, 1 mg
HCPCS Level II code Q5138 designates the intravenous biosimilar formulation of ustekinumab-auub (Wezlana), billed per 1 mg. This code captures administration and drug supply for an IV biologic replacement of reference ustekinumab products. Nationally, biosimilar coding matters for payer coverage policies, medication sourcing, and site-of-care payment differentials as health systems adopt biosimilars to manage biologic therapy costs and maintain clinical access.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical service represented by the code, typical sites of service, and payer coverage context. The publication summarizes available benchmarks and policy-relevant considerations for billing and reimbursement of an intravenous ustekinumab biosimilar, notes common billing modifiers and service-line placement when available, and outlines implications for infusion centers and hospital outpatient departments.
The content is intended to inform billing managers, revenue cycle staff, pharmacists, and policy analysts about the role of HCPCS Level II code Q5138 in clinical billing workflows and payer interactions, and to provide a baseline for tracking coverage updates and utilization patterns nationally.
Billing Code Overview
HCPCS Level II code Q5138 represents an intravenous biosimilar formulation of ustekinumab-auub (Wezlana) billed per 1 mg unit. The service is an intravenous biologic infusion used to deliver the biosimilar medication. The typical site of service is an outpatient infusion center or hospital outpatient department, where intravenous administration of biologic therapies is performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 46-year-old patient with moderate-to-severe plaque psoriasis refractory to topical therapy and phototherapy presents for intravenous induction dosing of a biosimilar ustekinumab product, Q5138 (wezlana), administered as an inpatient-observed or hospital outpatient infusion or in an infusion center. The clinical workflow begins with verification of the biologic order and insurance benefits, pre-infusion screening for active infection and tuberculosis, and baseline labs (CBC, CMP). The infusion visit includes patient identity confirmation, informed consent for intravenous biologic therapy, medication preparation and labeling by pharmacy, intravenous access placement, administration of the weight‑based Q5138 dose over the prescribed infusion time, and monitoring for infusion reactions for at least 30–60 minutes post‑infusion. Documentation includes indication, dose (mg), lot number, route intravenous, start/stop times, vital signs, any adverse events, and medication disposal records for wasted product. Follow-up scheduling for maintenance dosing and dermatology or rheumatology clinic coordination completes the workflow.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard service |